DCTH Delcath Systems, Inc.

0.02
+0.00  (4%)
Previous Close 0.02
Open 0.02
Price To book 0.00
Market Cap 2.85M
Shares 118,457,000
Volume 50,498,423
Short Ratio 0.24
Av. Daily Volume 15,264,100

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing as of November 2016.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
CRL September 13, 2013.
CHEMOSAT system
Unresectable metastatic ocular melanoma in the liver

Latest News

  1. Delcath Announces First Quarter 2017 Financial Results
  2. Delcath Issues Letter to Stockholders
  3. Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments
  4. Delcath Announces 2016 Financial Results
  5. Delcath Clinical Study Design Approved By FDA
  6. Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma
  7. Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017
  8. Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
  9. Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017
  10. New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium
  11. Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort
  12. DryShips, Merrimack Tumble into Friday’s 52-Week Low Club
  13. Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
  14. Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy
  15. Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases
  16. Here’s Why These Five Stocks Are on the Move Today
  17. Delcath Prices Underwritten Public Offering of Common Stock and Warrants

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17824310
  2. DEF 14A - Other definitive proxy statements 17818564
  3. PRER14A - Preliminary Proxy Soliciting materials 17806600
  4. 8-K - Current report 17786366
  5. PRE 14A - Other preliminary proxy statements 17756314
  6. 8-K - Current report 17732345
  7. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17720289
  8. 8-K - Current report 17678331
  9. 8-K - Current report 17630598
  10. 8-K - Current report 17628790